Star Equity Holdings, Inc. (STRR)
USD 1.97
(0.61%)
USD 1.97
(0.61%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -15.33 Million USD | -224.01% |
| 2022 | 12.36 Million USD | -4.0% |
| 2021 | 12.88 Million USD | -43.95% |
| 2020 | 22.98 Million USD | -5.0% |
| 2019 | 24.19 Million USD | 204.11% |
| 2018 | 7.95 Million USD | -54.86% |
| 2017 | 17.62 Million USD | -8.33% |
| 2016 | 19.22 Million USD | 226.95% |
| 2015 | -15.14 Million USD | -10.52% |
| 2014 | -13.7 Million USD | 26.21% |
| 2013 | -18.57 Million USD | 4.84% |
| 2012 | -19.51 Million USD | 18.82% |
| 2011 | -24.03 Million USD | -17.5% |
| 2010 | -20.45 Million USD | -50.88% |
| 2009 | -13.56 Million USD | -0.26% |
| 2008 | -13.52 Million USD | 8.05% |
| 2007 | -14.7 Million USD | -51.61% |
| 2006 | -9.7 Million USD | 36.04% |
| 2005 | -15.16 Million USD | -105.93% |
| 2004 | -7.36 Million USD | -184.09% |
| 2003 | 8.75 Million USD | 26.14% |
| 2002 | 6.94 Million USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -11.87 Million USD | 22.55% |
| 2024 Q2 | 11.63 Million USD | 211.41% |
| 2023 Q4 | -15.33 Million USD | 16.88% |
| 2023 FY | -15.33 Million USD | -224.01% |
| 2023 Q1 | 7.5 Million USD | -39.3% |
| 2023 Q3 | -18.45 Million USD | 5.66% |
| 2023 Q2 | -19.55 Million USD | -360.54% |
| 2022 Q4 | 12.36 Million USD | 34.82% |
| 2022 Q3 | 9.17 Million USD | 126.91% |
| 2022 Q1 | 4.91 Million USD | -61.85% |
| 2022 FY | 12.36 Million USD | -4.0% |
| 2022 Q2 | 4.04 Million USD | -17.74% |
| 2021 FY | 12.88 Million USD | -43.95% |
| 2021 Q2 | 10.15 Million USD | 55.09% |
| 2021 Q3 | 12.19 Million USD | 20.14% |
| 2021 Q4 | 12.88 Million USD | 5.62% |
| 2021 Q1 | 6.54 Million USD | -71.52% |
| 2020 Q1 | 23.97 Million USD | -0.89% |
| 2020 Q4 | 22.98 Million USD | 6.36% |
| 2020 Q3 | 21.6 Million USD | 10.95% |
| 2020 Q2 | 19.47 Million USD | -18.77% |
| 2020 FY | 22.98 Million USD | -5.0% |
| 2019 FY | 24.19 Million USD | 204.11% |
| 2019 Q1 | 15.53 Million USD | 95.29% |
| 2019 Q2 | 18.55 Million USD | 19.41% |
| 2019 Q3 | 24.87 Million USD | 34.07% |
| 2019 Q4 | 24.19 Million USD | -2.73% |
| 2018 Q3 | 12.62 Million USD | 13.88% |
| 2018 Q1 | 11.96 Million USD | -32.09% |
| 2018 Q4 | 7.95 Million USD | -37.01% |
| 2018 Q2 | 11.09 Million USD | -7.34% |
| 2018 FY | 7.95 Million USD | -54.86% |
| 2017 Q3 | 17.39 Million USD | 10.84% |
| 2017 FY | 17.62 Million USD | -8.33% |
| 2017 Q2 | 15.69 Million USD | -13.94% |
| 2017 Q4 | 17.62 Million USD | 1.3% |
| 2017 Q1 | 18.23 Million USD | -5.13% |
| 2016 Q3 | 20.34 Million USD | -4.55% |
| 2016 FY | 19.22 Million USD | 226.95% |
| 2016 Q4 | 19.22 Million USD | -5.51% |
| 2016 Q2 | 21.31 Million USD | -11.23% |
| 2016 Q1 | 24.01 Million USD | 258.54% |
| 2015 Q3 | -13.89 Million USD | 6.66% |
| 2015 Q2 | -14.88 Million USD | -7.28% |
| 2015 FY | -15.14 Million USD | -10.52% |
| 2015 Q1 | -13.87 Million USD | -1.26% |
| 2015 Q4 | -15.14 Million USD | -8.99% |
| 2014 Q2 | -11.57 Million USD | -21.26% |
| 2014 FY | -13.7 Million USD | 26.21% |
| 2014 Q4 | -13.7 Million USD | -7.11% |
| 2014 Q3 | -12.79 Million USD | -10.48% |
| 2014 Q1 | -9.54 Million USD | 48.58% |
| 2013 Q1 | -15.53 Million USD | 20.22% |
| 2013 FY | -18.57 Million USD | 4.84% |
| 2013 Q4 | -18.57 Million USD | -5.28% |
| 2013 Q3 | -17.63 Million USD | -36.22% |
| 2013 Q2 | -12.94 Million USD | 16.66% |
| 2012 FY | -19.51 Million USD | 18.82% |
| 2012 Q1 | -23.78 Million USD | 1.05% |
| 2012 Q4 | -19.47 Million USD | -6.16% |
| 2012 Q3 | -18.34 Million USD | 3.68% |
| 2012 Q2 | -19.04 Million USD | 19.94% |
| 2011 Q2 | -9.36 Million USD | 56.6% |
| 2011 Q4 | -24.03 Million USD | -134.34% |
| 2011 Q1 | -21.58 Million USD | -5.51% |
| 2011 FY | -24.03 Million USD | -17.5% |
| 2011 Q3 | -10.25 Million USD | -9.49% |
| 2010 Q2 | -14.81 Million USD | -9.77% |
| 2010 Q4 | -20.45 Million USD | -1.43% |
| 2010 FY | -20.45 Million USD | -50.88% |
| 2010 Q1 | -13.49 Million USD | 0.46% |
| 2010 Q3 | -20.17 Million USD | -36.15% |
| 2009 Q3 | -12.88 Million USD | 18.14% |
| 2009 Q4 | -13.56 Million USD | -5.28% |
| 2009 FY | -13.56 Million USD | -0.26% |
| 2009 Q2 | -15.73 Million USD | -2.66% |
| 2009 Q1 | -15.32 Million USD | -13.32% |
| 2008 Q1 | -15.35 Million USD | -4.36% |
| 2008 Q4 | -13.52 Million USD | -33.26% |
| 2008 Q3 | -10.14 Million USD | 9.57% |
| 2008 FY | -13.52 Million USD | 8.05% |
| 2008 Q2 | -11.22 Million USD | 26.89% |
| 2007 FY | -14.7 Million USD | -51.61% |
| 2007 Q4 | -14.7 Million USD | -60.61% |
| 2007 Q3 | -9.15 Million USD | 4.19% |
| 2007 Q2 | -9.55 Million USD | -1.95% |
| 2007 Q1 | -9.37 Million USD | 3.36% |
| 2006 FY | -9.7 Million USD | 36.04% |
| 2006 Q2 | -14.48 Million USD | 10.81% |
| 2006 Q3 | -3.88 Million USD | 73.16% |
| 2006 Q1 | -16.23 Million USD | -7.03% |
| 2006 Q4 | -9.7 Million USD | -149.6% |
| 2005 Q2 | -9.41 Million USD | -50.99% |
| 2005 FY | -15.16 Million USD | -105.93% |
| 2005 Q1 | -6.23 Million USD | 15.33% |
| 2005 Q3 | -9.55 Million USD | -1.48% |
| 2005 Q4 | -15.16 Million USD | -58.74% |
| 2004 Q1 | 6.93 Million USD | 0.0% |
| 2004 Q2 | -54.62 Million USD | -887.18% |
| 2004 Q3 | -23.18 Million USD | 57.55% |
| 2004 FY | -7.36 Million USD | -184.09% |
| 2004 Q4 | -7.36 Million USD | 68.23% |
| 2003 FY | 8.75 Million USD | 26.14% |
| 2002 FY | 6.94 Million USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 61.125% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | -159.332% |
| Aspira Women's Health Inc. | -331 Thousand USD | -4533.535% |
| Biodesix, Inc. | 34.3 Million USD | 144.705% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | -164.616% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -1133.938% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -1133.938% |
| Bionano Genomics, Inc. | 34.88 Million USD | 143.968% |
| CareDx, Inc | -47.97 Million USD | 68.032% |
| Check-Cap Ltd. | -24.75 Million USD | 38.047% |
| Castle Biosciences, Inc. | -83.53 Million USD | 81.639% |
| DarioHealth Corp. | -7.54 Million USD | -103.193% |
| Exact Sciences Corporation | 1.94 Billion USD | 100.787% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 81.425% |
| Guardant Health, Inc. | 220.22 Million USD | 106.964% |
| ICON Public Limited Company | 3.56 Billion USD | 100.431% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 103.105% |
| Illumina, Inc. | 1.21 Billion USD | 101.263% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | -182.311% |
| iSpecimen Inc. | -2.14 Million USD | -614.205% |
| Standard BioTools Inc. | 46.5 Million USD | 132.979% |
| MDxHealth SA | 18.88 Million USD | 181.213% |
| 23andMe Holding Co. | -141.37 Million USD | 89.151% |
| Medpace Holdings, Inc. | -103.32 Million USD | 85.157% |
| Myriad Genetics, Inc. | 88.1 Million USD | 117.409% |
| Mainz Biomed B.V. | 349.85 Thousand USD | 4483.816% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | -528.693% |
| NeoGenomics, Inc. | 269.19 Million USD | 105.697% |
| Neogen Corporation | 735.62 Million USD | 102.085% |
| Inotiv, Inc. | 382.14 Million USD | 104.013% |
| Natera, Inc. | -200.1 Million USD | 92.335% |
| OpGen, Inc. | 11.89 Million USD | 228.97% |
| OPKO Health, Inc. | 230.68 Million USD | 106.649% |
| Psychemedics Corporation | 334 Thousand USD | 4691.916% |
| Prenetics Global Limited | -43.33 Million USD | 64.61% |
| Prenetics Global Limited | -43.33 Million USD | 64.61% |
| Precipio, Inc. | -386 Thousand USD | -3873.316% |
| Personalis, Inc. | -8.02 Million USD | -91.187% |
| RadNet, Inc. | 1.14 Billion USD | 101.335% |
| Sera Prognostics, Inc. | -2.02 Million USD | -658.506% |
| Sotera Health Company | 2.02 Billion USD | 100.757% |
| Neuronetics, Inc. | 2.79 Million USD | 648.338% |
| Star Equity Holdings, Inc. | -15.33 Million USD | -0.0% |
| Trinity Biotech plc | 63.73 Million USD | 124.063% |
| T2 Biosystems, Inc. | 33.8 Million USD | 145.364% |
| Twist Bioscience Corporation | -192.4 Million USD | 92.029% |
| Exagen Inc. | -12.77 Million USD | -20.083% |